Core Insights - The company will present early preclinical data on its next-generation Emperor Total Artificial Heart at the ACC.26 conference in New Orleans from March 28 to March 30, 2026 [1][3] Company Overview - Picard Medical, Inc. is the parent company of SynCardia Systems LLC, which developed the first total artificial heart approved by both the U.S. FDA and Health Canada [1][7] - SynCardia's Total Artificial Heart is the only commercially available artificial heart technology in the U.S. and Canada, with over 2,100 implants performed across 27 countries [7] Product Development - The Emperor Total Artificial Heart is designed as a fully implantable electromechanical system that aims to preserve physiological autoregulation and hemodynamic performance [3][6] - The new system is intended to provide long-term support while improving mobility and quality of life for patients with advanced heart failure [6] Conference Participation - SynCardia will exhibit at booth 2554 during the ACC.26 conference, providing opportunities for attendees to meet with engineering and clinical teams [4][5] - The conference will serve as a platform for discussing the design, development progress, and future clinical direction of the Emperor Total Artificial Heart [5]

Core Insights - Picard Medical, Inc. is set to present data on its fully implantable Emperor Total Artificial Heart at the upcoming 19th EUMS & 11th International Course on MCS and New Technologies in Advanced Heart Failure congress in Barcelona, Spain from February 15-18, 2026 [1][2] Company Overview - Picard Medical, Inc. is the parent company of SynCardia Systems, LLC, which is the only provider of commercially available total artificial heart technology for patients with end-stage heart failure [3] - The SynCardia Total Artificial Heart (STAH) is the first artificial heart approved by both the U.S. FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada [3] - Over 2,100 implants of the SynCardia Total Artificial Heart have been performed in hospitals across 27 countries, making it the most widely used and extensively studied artificial heart globally [3] Event Details - The presentation titled "The Emperor Rises: First In Vitro and In Vivo Evaluation of SynCardia's Electromechanical Total Artificial Heart" will take place on February 16, 2026, from 17:15 to 18:15 Central European Time [2] - The European Mechanical Circulatory Support Summit (EUMS) serves as a leading international forum for advancing mechanical circulatory support and emerging technologies in treating advanced heart failure [2]

Core Insights - Picard Medical, Inc. is the parent company of SynCardia Systems LLC, which produces the world's first total artificial heart approved by both the U.S. FDA and Health Canada [1][3] - CEO Patrick NJ Schnegelsberg will present data on the Emperor Total Artificial Heart at the CSI Focus D-HF conference in Frankfurt, Germany, on December 6, 2025 [1][2] Company Overview - Picard Medical, Inc. is based in Tucson, Arizona, and is a leader in total artificial heart technology for patients with end-stage heart failure [3] - The SynCardia Total Artificial Heart (STAH) is the only commercially available artificial heart in the U.S. and Canada, having been implanted over 2,100 times across 27 countries, making it the most widely used and studied artificial heart globally [3]

Core Viewpoint - Picard Medical, Inc. will present in vitro data on its fully implantable Emperor Total Artificial Heart at the ISMCS 2025 conference, highlighting advancements in patient mobility and quality of life [1][3]. Group 1: Presentation Details - The presentation is scheduled for December 4, 2025, at 14:05 CET during the Mini Oral Session 3 focused on Hemocompatibility and Heart/Pump Interaction [2]. - The title of the presentation is "The Emperor Total Artificial Heart: A Next Generation, Fully Implantable Total Artificial Heart," and it will be presented by Duffy Elmer, Engineering Project Manager at Picard Medical [2]. Group 2: Product Information - The Emperor Total Artificial Heart features an internal motor-driven design that eliminates the need for an external pneumatic driver, aiming to enhance patient mobility and overall quality of life [3]. - Picard Medical, through its subsidiary SynCardia Systems, is the only company with commercially available total artificial heart technology for patients with end-stage heart failure, having performed over 2,100 implants across 27 countries [5]. Group 3: Event Information - ISMCS 2025 is the 31st annual global congress of the International Society for Mechanical Circulatory Support, bringing together various stakeholders to discuss new clinical research and emerging technologies in mechanical circulatory support [4].